Romasko Edward J, Devkota Batsal, Biswas Sawona, Jayaraman Vijayakumar, Rajagopalan Ramakrishnan, Dulik Matthew C, Thom Christopher S, Choi Jiwon, Jairam Sowmya, Scarano Maria I, Krantz Ian D, Spinner Nancy B, Conlin Laura K, Lambert Michele P
Division of Human Genetics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Am J Hematol. 2018 Jan;93(1):8-16. doi: 10.1002/ajh.24917. Epub 2017 Oct 20.
Inherited platelet disorders (IPD) are a heterogeneous group of rare disorders that affect platelet number and function and often predispose to other significant medical complications. In spite of the identification of over 50 IPD disease-associated genes, a molecular diagnosis is only identified in a minority (10%) of affected patients without a clinically suspected etiology. We studied a cohort of 21 pediatric patients with suspected IPDs by exome sequencing (ES) to: (1) examine the performance of the exome test for IPD genes, (2) determine if this exome-wide diagnostic test provided a higher diagnostic yield than has been previously reported, (3) to evaluate the frequency of variants of uncertain significance identified, and (4) to identify candidate variants for functional evaluation in patients with an uncertain or negative diagnosis. We established a high priority gene list of 53 genes, evaluated exome capture kit performance, and determined the coverage for these genes and disease-related variants. We identified likely disease causing variants in 5 of the 21 probands (23.8%) and variants of uncertain significance in 52% of patients studied. In conclusion, ES has the potential to molecularly diagnose causes of IPD, and to identify candidate genes for functional evaluation. Robust exome sequencing also requires that coverage of genes known to be associated with clinical findings of interest need to be carefully examined and supplemented if necessary. Clinicians who undertake ES should understand the limitations of the test and the full significance of results that may be returned.
遗传性血小板疾病(IPD)是一组异质性罕见疾病,会影响血小板数量和功能,且常常易引发其他严重的医学并发症。尽管已鉴定出50多个与IPD疾病相关的基因,但在没有临床疑似病因的受影响患者中,只有少数(10%)能得到分子诊断。我们通过外显子组测序(ES)研究了一组21例疑似IPD的儿科患者,目的是:(1)检查外显子组检测对IPD基因的性能;(2)确定这种全外显子组诊断检测是否能提供比先前报道更高的诊断率;(3)评估鉴定出的意义不明确变异的频率;(4)识别诊断不明确或为阴性的患者中用于功能评估的候选变异。我们建立了一个包含53个基因的高优先级基因列表,评估了外显子组捕获试剂盒的性能,并确定了这些基因和疾病相关变异的覆盖范围。我们在21名先证者中的5名(23.8%)中鉴定出可能致病的变异,在52%的研究患者中鉴定出意义不明确的变异。总之,ES有潜力从分子层面诊断IPD的病因,并识别用于功能评估的候选基因。强大的外显子组测序还要求仔细检查已知与感兴趣临床发现相关的基因覆盖范围,并在必要时进行补充。进行ES的临床医生应了解该检测的局限性以及可能返回结果的全部意义。